Literature DB >> 10636620

Inhibition of cyclooxygenase 2 by nimesulide decreases prostaglandin E2 formation but does not alter brain edema or clinical recovery after closed head injury in rats.

L Koyfman1, J Kaplanski, A A Artru, D Talmor, M Rubin, Y Shapira.   

Abstract

Recently, the enzyme cyclooxygenase (COX) has been recognized to exist as constitutive (COX-1) and inducible isoforms (COX-2). In previous studies, drugs that were inhibitors of both COX-1 and COX-2 failed to decrease brain edema formation or improve Neurological Severity Score (NSS) after closed head trauma (CHT), although some did decrease prostaglandin-E2 (PGE2) formation. The present study examined whether or not a specific inhibitor of COX-2 (nimesulide) exerts a beneficial effect after CHT in rats. Halothane-anesthetized rats (n = 8 in each group) were randomly assigned to one of four groups: surgery, no CHT, no drug (group 1); surgery, no CHT, nimesulide 30 mg/kg intraperitoneally (IP) (group 2); surgery, CHT, no drug (group 3); and surgery, CHT, nimesulide 30 mg/kg IP (group 4). NSS was determined at 1 and 24 h, and brain tissue PGE2 concentration and water content were determined after killing at 24 h. Treatment with nimesulide did not improve NSS (NSS at 24 h = 11+/-6 [median +/- range] in group 3 and 12+/-4 in group 4) or edema formation (brain water content at 24 h = 84.3+/-1.8% [mean +/- SD] in group 3 and 83.8+/-1.9% in group 4). However, nimesulide did decrease cortical and hypothalamic PGE2 formation by 41% and 47%, respectively during the first hour of incubation after brain tissue sampling. The authors conclude that although nimesulide does reduce tissue PGE2 formation, it does not exert a beneficial effect on brain tissue edema or functional activity after CHT in rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10636620     DOI: 10.1097/00008506-200001000-00009

Source DB:  PubMed          Journal:  J Neurosurg Anesthesiol        ISSN: 0898-4921            Impact factor:   3.956


  6 in total

Review 1.  Bridge between neuroimmunity and traumatic brain injury.

Authors:  Matthew L Kelso; Howard E Gendelman
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 2.  Pharmacological treatment of traumatic brain injury: a review of agents in development.

Authors:  J Hatton
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

3.  Genetic disruption of cyclooxygenase-2 does not improve histological or behavioral outcome after traumatic brain injury in mice.

Authors:  Muzamil Ahmad; Marie E Rose; Vincent Vagni; Raymond P Griffith; C Edward Dixon; Patrick M Kochanek; Robert W Hickey; Steven H Graham
Journal:  J Neurosci Res       Date:  2008-12       Impact factor: 4.164

4.  Effects of genetic deficiency of cyclooxygenase-1 or cyclooxygenase-2 on functional and histological outcomes following traumatic brain injury in mice.

Authors:  Matthew L Kelso; Stephen W Scheff; James R Pauly; Charles D Loftin
Journal:  BMC Neurosci       Date:  2009-08-31       Impact factor: 3.288

5.  Effects of Subchronic Treatment with Ibuprofen and Nimesulide on Spatial Memory and NMDAR Subunits Expression in Aged Rats.

Authors:  Ozlem Ozturk Bilgin; Duygu Kumbul Doguc; Irfan Altuntas; Recep Sutcu; Namık Delibas
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

6.  A Systematic Review of Closed Head Injury Models of Mild Traumatic Brain Injury in Mice and Rats.

Authors:  Colleen N Bodnar; Kelly N Roberts; Emma K Higgins; Adam D Bachstetter
Journal:  J Neurotrauma       Date:  2019-03-06       Impact factor: 5.269

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.